Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Karenitecin vs Topotecan in Advanced Epithelial Ovarian Cancer
NCT00477282Phase 3Completed
- Sponsor
- BioNumerik Pharmaceuticals
- Start
- Aug 2007
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of karenitecin in epithelial ovarian cancer (EOC) (2 arms), sponsored by BioNumerik Pharmaceuticals. Primary endpoint: Progression Free Survival. Started Aug 2007; status: completed.
02
Drugs
karenitecin
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NCT00477282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00477282.